FY22 Appropriations funding.
FY22 NDAA - provisions related to biological and chemical defense and access to naloxone.
S.4231 - Preparing for the Next Pandemic Act.
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
State Opioid Response Grants funding.
Substance Abuse and Mental Health Block Grant funding.
CARA 3.0 - Comprehensive Addiction and Recovery Act.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021.
H.R. 2366 and S. 1457 - the Stop Fentanyl Act.
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021.
Duration: August 1, 2013
to
December 31, 2021
General Issues: Budget/Appropriations , Defense , Disaster Planning/Emergencies , Health Issues , Homeland Security , Chemicals/Chemical Industry
Spending: about $1,070,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: House of Representatives, U.S. Senate, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), Natl Guard, Defense - Dept of (DOD),, Defense - Dept of (DOD), Army - Dept of (Other)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tony Corwin Inspect. Gen. of the Marine Corps
Legis. Asst. to the Commandant of Marine Corps
Inspect. Gen. of the Marine Corps; Legis. Asst. to the Commandant of Marine Corps
Stephen Peranich Chief of Staff to Congressman Gene Taylor
Kate Anderson Leg. Correspondent, Senator Susan Collins
E. Peter Giambastiani III Dep. COS for Congressman Jeff Miller
Spec. Asst. to Dep. UnderSecretary of the Navy
Jennifer Ellison Staff Assistant, House Armed Services Committee (2004-2006)
Genevieve Cowan Legislative Analyst, Joint Committee on Taxation (2015-2017); Legal Research Assistant, Joint Committee on Taxation (2011-2015)
Mike Legg Director of Operations, House Committee on Transportation and Infrastructure (2012-2019)
Katherine Anderson n/a
C.J. Zane n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
BLANK ROME GOVERNMENT RELATIONS terminated an engagement in which they represented Emergent BioSolutions Inc. on Jan. 20, 2022.
Original Filing: 301333490.xml
Lobbying Issues
FY22 Appropriations funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY22 NDAA - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act.
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding.
Substance Abuse and Mental Health Block Grant funding.
CARA 3.0 - Comprehensive Addiction and Recovery Act.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021.
H.R. 2366 and S. 1457 - the Stop Fentanyl Act.
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Oct. 19, 2021.
Original Filing: 301306015.xml
Lobbying Issues
FY22 Appropriations funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY22 NDAA - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act.
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding.
Substance Abuse and Mental Health Block Grant funding.
CARA 3.0 - Comprehensive Addiction and Recovery Act.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021.
H.R. 2366 and S. 1457 - the Stop Fentanyl Act.
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on July 19, 2021.
Original Filing: 301282393.xml
Lobbying Issues
FY22 Appropriations funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY22 NDAA - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding.
Substance Abuse and Mental Health Block Grant funding.
CARA 3.0 - Comprehensive Addiction and Recovery Act.
Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021.
H.R. 2366 and S. 1457 - the Stop Fentanyl Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on April 20, 2021.
Original Filing: 301261627.xml
Lobbying Issues
FY22 Appropriations funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY22 NDAA - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4231 - Preparing for the Next Pandemic Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding.
Substance Abuse and Mental Health Block Grant funding.
CARA 3.0 - Comprehensive Addiction and Recovery Act.
Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 21, 2021.
Original Filing: 301243849.xml
Lobbying Issues
Consolidated Appropriations Act for 2021 (P.L. 116-260).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2021 National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense and access to naloxone (P.L. 116-283).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 14 - The Commitment to Defeat the Virus and Keep America Healthy Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding for FY 2021.
Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
H.R. 2466 - The State Opioid Response Grant Authorization Act.
H.R. 7783/S. 4179 - Plasma Donation Awareness Acts of 2020, to add plasma to blood donation awareness campaign.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 4231 - Preparing for the Next Pandemic Act.
H.R. 8406 - The Heroes Act.
HEALS Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Oct. 19, 2020.
Original Filing: 301216876.xml
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding for FY 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 17, 2020.
Original Filing: 301192098.xml
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
State Opioid Response Grants funding for FY 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301176969.xml
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.
S.3548 - CARES Act.
FY 2021 Appropriations provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127864.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA), S. 1790 and H.R. 2500 - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Oct. 18, 2019.
Original Filing: 301071007.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA), S. 1790 and H.R. 2500 - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301058492.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA), S. 1790 - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 18, 2019.
Original Filing: 301030103.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016919.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Department of Defense Appropriations for Medical Countermeasures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
FDA regulatory issues.
Issues related to Priority Voucher Review programs.
Opioid and heroin addiction legislation.
Naloxone access, co-prescribing opioid guidelines.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996511.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300976890.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on April 20, 2018.
Original Filing: 300957897.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
National Defense Authorization Act (NDAA) - provisions related to biological and chemical defense.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 22, 2018.
Original Filing: 300937163.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
FY 2018 National Defense Authorization Act (NDAA) (H.R. 2810 and S. 1519), provisions related to biological and chemical defense.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2017
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Oct. 20, 2017.
Original Filing: 300916772.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
FY 2018 National Defense Authorization Act (NDAA) (H.R. 2810 and S. 1519), provisions related to biological and chemical defense.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2017
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on July 20, 2017.
Original Filing: 300896636.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2017
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $10,000. The report was filed on April 19, 2017.
Original Filing: 300869886.xml
Lobbying Issues
FY 2017 and FY 2018 Appropriations and FY 2018 President's budget request - issues related to development, acquisition, and stockpiling of medical countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2017 and FY 2018 Appropriations - issues related to development, acquisition, and stockpiling of medical countermeasures
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2017 and FY 2018 Appropriations - issues related to development, acquisition, and stockpiling of medical countermeasures
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2016
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856422.xml
Lobbying Issues
Issues relating to FY 2017 federal funding for the National Biodefense Plan and chemical decontamination, including in FY 17 National Defense Authorization Act (H.R. 4909, S. 2943)
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Defense Authorization Act for Fiscal Year 2017 - issues related to the National Biodefense Plan and chemical decontamination.
Issues relating to H.R. 4909 and S. 2943, FY 17 National Defense Authorization Act;
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915;
Strengthening Public Health Emergency Response Act, H.R. 3299
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Issues related to H.R. 34, the 21st Century Cures Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837112.xml
Lobbying Issues
Issues relating to FY 2017 federal funding for the National Biodefense Plan and chemical decontamination, including in FY 17 National Defense Authorization Act (H.R. 4909, S. 2943), FY 17 Defense Appropriations bills (H.R. 5293, S. 3000), and Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017 (H.R. 5325)
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Defense Authorization Act for Fiscal Year 2017 - issues related to the National Biodefense Plan and chemical decontamination.
Issues relating to H.R. 4909 and S. 2943, FY 17 National Defense Authorization Act;
FY 17 Defense Appropriations bills (H.R. 5293, S. 3000) and H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017
Funding for DHS, HHS, and DOD programs related to pandemics, infectious diseases, and chemical and biological threats.
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915;
Strengthening Public Health Emergency Response Act, H.R. 3299
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2016
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300818660.xml
Lobbying Issues
Issues relating to FY 2017 federal funding for pandemics, tropical infectious diseases, chemical and biodefense programs and US government preparation and response, including in FY 17 Labor, HHS, & Education Appropriations (S. 3040, House bill currently unnamed), FY 17 Defense Appropriations (S. 3000), and the National Defense Authorization Act (H.R. 4909)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to H.R. 4909, FY 17 National Defense Authorization Act;
FY 17 Defense Appropriations bills (H.R. 5293, S. 3000), FY 17 Labor-HHS-Education Appropriations bills (S. 3040, House bill unnamed), and FY 17 Homeland Security Appropriations bills (S.3001, H.R.5634);
Funding for DHS, HHS, and DOD programs related to pandemics, infectious diseases, and chemical and biological threats.
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915;
Strengthening Public Health Emergency Response Act, H.R. 3299
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2016
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300800090.xml
Lobbying Issues
Issues relating to FY 2017 federal funding for pandemics, tropical infectious diseases, chemical and biodefense programs and US government preparation and response.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to H.R. 4909, FY 17 National Defense Authorization Act;
H.R. 2029, Consolidated Appropriations Act, 2016;
FY 17 Defense, HHS, and DHS Appropriations bills;
Funding for DHS, HHS, and DOD programs related to pandemics, infectious diseases, and chemical and biological threats.
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915
Strengthening Public Health Emergency Response Act, H.R. 3299
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2015
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300780616.xml
Lobbying Issues
Issues relating to FY 2016 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2016 Appropriations Bills (H.R. 2685, S. 1558, and H.R. 2029)
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915
Strengthening Public Health Emergency Response Act, H.R. 3299
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2015
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300762076.xml
Lobbying Issues
Issues relating to FY 2016 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2016 Appropriations Bills (H.R. 2685, S. 1588)
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300 and S. 1915
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2015
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300742032.xml
Lobbying Issues
Issues relating to FY 2016 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2016 Appropriations Bills (H.R. 2685, S. 1588)
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2015
BLANK ROME GOVERNMENT RELATIONS amended a lobbying report for representation of Emergent BioSolutions Inc. in Q12015 on April 23, 2015.
Original Filing: 300728640.xml
Lobbying Issues
Issues relating to FY 2016 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2016 Appropriations Bills
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2015
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on April 20, 2015.
Original Filing: 300723409.xml
Lobbying Issues
Issues relating to FY 2016 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2016 Appropriations Bills
Agencies Lobbied
U.S. Senate
Lobbying Issues
First Responders Anthrax Preparedness Act, H.R. 1300
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2014
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704438.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2015 Appropriations Bills (H.R. 4870, H.R. 4903, S.2534)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to FY 2015 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL);
H.R. 4870, the Department of Defense Appropriations Act, 2015;
H.R. 4903 and S. 2534, Department of Homeland Security Appropriations Act, 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Chemical Facility Anti-Terrorism Security (CFATS) legislation and Executive Order
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
3rd Quarter, 2014
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678603.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2015 Appropriations Bills (H.R. 4870, H.R. 4903, S.2534)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to FY 2015 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Chemical Facility Anti-Terrorism Security (CFATS) legislation and Executive Order
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
2nd Quarter, 2014
In Q2, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300663087.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the FY 2015 Appropriations Bills (H.R. 4870, H.R. 4903, S.2534)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to FY 2015 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Chemical Facility Anti-Terrorism Security (CFATS) legislation and Executive Order
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2014
BLANK ROME GOVERNMENT RELATIONS amended a lobbying report for representation of Emergent BioSolutions Inc. in Q12014 on April 21, 2014.
Original Filing: 300646763.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the National Defense Authorization Act and in FY 2014 Appropriations Bills (S. 1429)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to FY 2015 federal funding opportunities for Reactive Skin Decontamination Lotion (RSDL)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Chemical Facility Anti-Terrorism Security (CFATS) legislation and Executive Order
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Chemicals/Chemical Industry
1st Quarter, 2014
In Q1, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Feb. 7, 2014.
Original Filing: 300630121.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the National Defense Authorization Act (H.R. 1960) and in FY 2014 Appropriations Bills
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 21, 2014.
Original Filing: 300622688.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the National Defense Authorization Act (H.R. 1960) and in FY 2014 Appropriations Bills
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, BLANK ROME GOVERNMENT RELATIONS lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 21, 2013.
Original Filing: 300601771.xml
Lobbying Issues
Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the National Defense Authorization Act (H.R. 1960) and in FY 2014 Appropriations Bills
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
BLANK ROME GOVERNMENT RELATIONS filed a lobbying registration on Sept. 29, 2013 to represent Emergent BioSolutions Inc., effective Aug. 1, 2013.
Original Filing: 300590154.xml
Issue(s) they said they’d lobby about: Issues relating to Reactive Skin Decontamination Lotion (RSDL), including relevant provisions in the National Defense Authorization Act (H.R. 1960) and in FY 2014 Appropriations Bills .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...